JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Project Announcements
Bosch Expands Lincolnton, North Carolina, Operations
06/02/2023
Little Leaf Farms Establishes McAdoo, Pennsylvania, Greens Production Complex
06/02/2023
Swiss-Based Sulzer Pumps Solutions Plans Easley, South Carolina, Operations
06/01/2023
Finland-Based ADMARES Plans Waycross, Georgia, U.S. Manufacturing Plant
06/01/2023
Toyota Plans Georgetown, Kentucky, Electric Vehicle Operations
06/01/2023
Ranger Design Establishes North Charleston, South Carolina, Operations
05/31/2023
Most Read
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
Is a Flurry of Fads Shaping Economic Development Policy?
Q2 2023
-
Nearshoring — North America’s Next Factory
Q2 2023
-
Front Line: Water Supply Increasingly Affecting Location Decisions
Q2 2023
-
Life Science Conversions in Real Estate
Q2 2023
-
First Person: Labor Crunch in the Construction Industry
Q2 2023
-
Companies Are Recalibrating Their Priorities
Q1 2023